Ghost Tree Capital’s Verona Pharma VRNA Stock Holding History

Ghost Tree Capital’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,000	Closed	-$596K	–	81
2023 Q4	$596K	Sell	30,000 -15,000	-33%	-$221K	0.2%	52
2023 Q3	$734K	Sell	45,000 -65,000	-59%	-$1.25M	0.24%	62
2023 Q2	$2.33M	Buy	+110,000	New	+$2.35M	0.77%	35
2022 Q2	–	Sell	-750,000	Closed	-$3.74M	–	44
2022 Q1	$3.74M	Hold	750,000	–	–	0.81%	24
2021 Q4	$5.04M	Hold	750,000	–	–	1.81%	20
2021 Q3	$4.11M	Sell	750,000 -250,000	-25%	-$1.45M	1.2%	34
2021 Q2	$6.54M	Buy	1,000,000 +60,957	+6%	+$423K	1.8%	18
2021 Q1	$7.85M	Buy	939,043 +129,043	+16%	+$1.07M	1.85%	18
2020 Q4	$5.67M	Buy	810,000 +4,444	+0.6%	+$30K	1.26%	27
2020 Q3	$5.03M	Buy	+805,556	New	+$5.57M	1.45%	23

Other funds holding VRNA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ghost Tree Capital's VRNA Position: Q1 2024 in Review

Ghost Tree Capital sold out of Verona Pharma (VRNA) in Q1 2024, closing a stake of 30,000 shares — an estimated $596K sold.

Ghost Tree Capital first reported a position in VRNA in Q3 2020 and held it in 10 quarters. The position peaked at $7.85M in Q1 2021. 113 funds tracked by Wall St. Rank hold VRNA as of Q1 2024.

Ghost Tree Capital reported no remaining Verona Pharma position as of Q1 2024 after selling out during the quarter.
Ghost Tree Capital sold 30,000 Verona Pharma shares in Q1 2024, an estimated $596K.
Ghost Tree Capital first reported a position in Verona Pharma in Q3 2020 and held it in 10 quarters.
Ghost Tree Capital's Verona Pharma position peaked at $7.85M in Q1 2021.
113 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2024.

Based on Ghost Tree Capital's 13F filing for Q1 2024, filed 15 May 2024.